<DOC>
	<DOCNO>NCT02235987</DOCNO>
	<brief_summary>The study design investigate safety , tolerability efficacy DG3173 untreated acromegaly patient . Twenty patient receive ascend single dos DG3173 one dose octreotide , current gold standard medical therapy acromegaly , patient receiving dos DG3173 well octreotide .</brief_summary>
	<brief_title>Single Dose Pharmacology Study DG3173 Octreotide Acromegalic Patients .</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Men , woman non childbearing potential woman child bear potential either abstain sexual intercourse , sterile partner practice medically approve double barrier method contraception Diagnosis acromegaly pituitary origin Have age adjust Insulin like Growth Factor 1 ( IGF1 ) concentration ≥1.5 time upper limit normal range two consecutive measurement 6 month prior first dose day ( include measurement make screen [ Visit 2 ] ) Have random hGH level ≥5 µg/L 6 month prior screen ( Visit 2 ) Have give write informed consent Ability comply requirement protocol study Previous specific treatment acromegaly 6 month prior screen ( Visit 2 ) , include somatostatin analogue ( SSAs ) , surgery , radiotherapy pegvisomant Treatment dopamine agonists 3 month prior screen ( Visit 2 ) Uncontrolled hypertension orthostatic hypotension Type I diabetes mellitus , poorlycontrolled type II diabetes mellitus ( glycosylated haemoglobin [ HbA1c ] ≥7.5 % ) patient require insulin treatment Gallstones gravel could cause biliary obstruction Hyperprolactinaemia Participation clinical study within 60 day prior screen ( Visit 2 ) Receipt blood , blood product plasma derivative 60 day prior screen ( Visit 2 ) Pregnancy lactation A history active alcohol abuse drug addiction Positive viral serology screen result hepatitis B surface antigen , antibody hepatitis C virus , human immunodeficiency virus type 1 2 Evidence suspicion tumour expansion Clinically significant abnormality screen ECG Any clinically significant abnormal laboratory safety test ( biochemistry , haematology dipstick urinalysis ) opinion Investigator Any disease Investigator 's opinion would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>